In schizophrenia, controlling residual symptoms, negative symptoms (e.g. social withdrawal, flattened affect and depression), diminished quality of life and functional impairment remains a challenge with limited treatment options.
First generation antipsychotics cause extrapyramidal side effects and movement disorders while second-generation APDs lead to weight gain and metabolic alterations. Consequently, there is a tremendous unmet medical need in disease management.
ITI-007, a new molecular entity, is a high-affinity antagonist at the serotonin 2A (5-HT2A) receptor with lower affinity for D2 receptors, among other targets. It has a sixty-fold separation between its affinity for 5-HT2A receptors and D2 receptors, much wider than other antipsychotics.
Improved negative symptoms but not significantly at 60mgs. No improvement at 120 mgs.
Its the neg symptoms im concerned abt. Nothing currently exists to treat them and they are ruining my life. I only have 1 neg symptom alogia but it is very persistent.
Why are ppl so excited abt iti007 anyway? U cant feel the metabolic effects of aps and there are already weight neutral aps like latuda and abilify.
And all that heart rate stuff, that stuff isn’t something u can see or measure. Iti007 is just going to be another antipsychotic in my opinion. And it probably wont help me with my neg symptoms.
Im looking forward to min-101—hopefully that does something for my alogia.
